


Prexasertib dimesylate

Cat. No.:	HY-18174E
CAS No.:	1234015-58-7
Molecular Formula:	C ₂₀ H ₂₇ N ₇ O ₈ S ₂
Molecular Weight:	557.6
Target:	Checkpoint Kinase (Chk); Apoptosis
Pathway:	Cell Cycle/DNA Damage; Apoptosis
Storage:	4°C, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (179.34 mM; Need ultrasonic)					
	H ₂ O : 50 mg/mL (89.67 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent	Mass	1 mg	5 mg	10 mg
		Concentration				
		1 mM		1.7934 mL	8.9670 mL	17.9340 mL
5 mM			0.3587 mL	1.7934 mL	3.5868 mL	
10 mM		0.1793 mL	0.8967 mL	1.7934 mL		
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 3.5 mg/mL (6.28 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 3.5 mg/mL (6.28 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	Prexasertib dimesylate (LY2606368 dimesylate) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a K _i of 0.9 nM and an IC ₅₀ of <1 nM. Prexasertib dimesylate inhibits CHK2 (IC ₅₀ =8 nM) and RSK1 (IC ₅₀ =9 nM). Prexasertib dimesylate causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib dimesylate shows potent anti-tumor activity ^{[1][2]} .		
IC₅₀ & Target	Chk1 0.9 nM (K _i)	Chk1 <1 nM (IC ₅₀)	Chk2 8 nM (IC ₅₀)
In Vitro	Prexasertib dimesylate (LY2606368 dimesylate) inhibits MELK (IC ₅₀ =38 nM), SIK (IC ₅₀ =42 nM), BRSK2 (IC ₅₀ =48 nM), ARK5 (IC ₅₀ =64 nM). Prexasertib dimesylate requires CDC25A and CDK2 to cause DNA damage ^[1] .		

Prexasertib dimesylate (33, 100 nM; for 7 hours) results in DNA damage during S-phase in HeLa cells^[1].
 Prexasertib dimesylate (8-250 nM; pre-treated for 15 minutes) inhibits CHK1 autophosphorylation (S296) and CHK2 autophosphorylation (S516) in HT-29 cells^[1].
 Prexasertib dimesylate (4 nM; 24 hours) results in a large shift in cell-cycle populations from G1 and G2-M to S-phase with an accompanied induction of H2AX phosphorylation in U-2 OS cells^[1].
 Prexasertib dimesylate (33 nM; for 12 hours) causes chromosomal fragmentation in HeLa cells. Prexasertib dimesylate (100 nM; 0.5 to 9 hours) induces replication stress and depletes the pool of available RPA2 for binding to DNA^[1].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis^[1]

Cell Line:	HeLa cells
Concentration:	33, 100 nM
Incubation Time:	For 7 hours
Result:	Had an IC ₅₀ of 37 nM and resulted in the G2-M population received DNA damage during S-phase but continued to progress through the cell cycle into an early mitosis.

Western Blot Analysis^[1]

Cell Line:	HT-29 cells
Concentration:	8, 16, 31, 63, 125, 250 nM
Incubation Time:	Pre-treated for 15 minutes
Result:	Inhibited CHK1 autophosphorylation (S296) and CHK2 autophosphorylation (S516) (IC ₅₀ of less than 31 nM) in HT-29 cells.

In Vivo

Prexasertib dimesylate (LY2606368 dimesylate; 1-10 mg/kg; SC; twice daily for 3 days, rest 4 days; for three cycles) causes growth inhibition in tumor xenografts^[1].
 Prexasertib dimesylate (15 mg/kg; SC) causes CHK1 inhibition in the blood and the phosphorylation of both H2AX (S139) and RPA2 (S4/S8)^[1].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female CD-1 nu-/nu- mice (26-28 g) with Calu-6 cells ^[1]
Dosage:	1, 3.3, or 10 mg/kg
Administration:	SC; twice daily for 3 days, rest 4 days; for three cycles
Result:	Caused statistically significant tumor growth inhibition (up to 72.3%).

Animal Model:	Female CD-1 nu-/nu- mice (26-28 g) with Calu-6 cells ^[1]
Dosage:	15 mg/kg (Pharmacokinetic Analysis)
Administration:	SC (200 µL)
Result:	CHK1 was 7 ng/mL at 12 hours and 3 ng/mL by 24 hours in plasma exposures. Phosphorylation of both H2AX (S139) and RPA2 (S4/S8) was detectable at 4 hours, showing the rapid occurrence of DNA damage.

CUSTOMER VALIDATION

- Nat Commun. 2019 Aug 2;10(1):3485.
- Cancers (Basel). 2020 Aug 26;12(9):E2426.
- Cancers (Basel). 2020 Jun 29;12(7):E1726.
- Mol Cancer Res. 2019 Oct;17(10):2102-2114.
- Methods Mol Biol. 2018;1711:351-398.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. King C, et al. LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms. Mol Cancer Ther. 2015 Sep;14(9):2004-1
- [2]. Yin Y, et al. Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer. Am J Cancer Res. 2017 Mar 1;7(3):473-483.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA